KR20090058567A - 자기 보존 수성 약제학적 조성물 - Google Patents
자기 보존 수성 약제학적 조성물 Download PDFInfo
- Publication number
- KR20090058567A KR20090058567A KR1020097007721A KR20097007721A KR20090058567A KR 20090058567 A KR20090058567 A KR 20090058567A KR 1020097007721 A KR1020097007721 A KR 1020097007721A KR 20097007721 A KR20097007721 A KR 20097007721A KR 20090058567 A KR20090058567 A KR 20090058567A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- concentration
- zinc
- compositions
- present
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
박테리아 | 진균 | |
USP 27 | 7일까지 1 로그 (90%); 14일까지 3 로그 (99.9%) 감소; 및 14일 후 증가 없음 | 조성물은 총 시험 기간에 걸쳐 증명되어야 하고 (demonstrate), 이는 초기 접종량에 비해 0.5 로그 이상 증가가 없음을 의미한다. |
일본 | 14일까지 3 로그; 및 14일에서 28일까지 증가 없음 | 초기 계수로부터 14일 및 28일에서 증가 없음 |
Ph.Eur.A1 | 6시간까지 2 로그 (99%); 24시간까지 3 로그 감소; 및 28일 후 회복 (recovery) 없음 | 7일까지 2 로그 (99%) 감소 및 그 후 증가 없음 |
Ph.Eur.B | 24시간까지 1 로그; 7일까지 3 로그 감소; 및 그 후 증가 없음 | 14일까지 1 로그 (90%) 감소 및 그 후 증가 없음 |
FDA/ISO 14730 | 초기 공격에서 14일까지 3 로그 감소; 재공격까지 3 로그 감소 | 14일에 초기값 이상으로 증가 없고, 재공격에서 28일까지 14일 이상의 증가 없음 |
풀링 시간 (time pulls) | 24시간 | 7일 | 14일 | 28일 |
박테리아 (황색포도상구균, 녹농균 및 대장균)에 대하여 | ||||
Ph. Eur. B | 1.0 | 3.0 | NI | NI |
USP | NA | 1.0 | 3.0 | NI |
진균 (칸디다 알비칸스 및 아스페르길루스 니거)에 대하여 | ||||
Ph. Eur. B | NA | NA | 1.0 | NI |
USP | NA | NI | NI | NI |
Claims (18)
- 아연 이온을 0.04 내지 0.9 mM의 농도로 포함하고, 조성물중에 존재하는 음이온성 종의 농도가 15 mM 미만인 다회-용량의 자기 보존 안과 조성물.
- 제 1항에 있어서, 항균 유효량의 붕산염을 추가로 포함하는 것을 특징으로 하는 조성물.
- 제 1항에 있어서, 붕산염/폴리올 복합체를 추가로 포함하는 것을 특징으로 하는 조성물.
- 제 3항에 있어서, 붕산염/폴리올 복합체에 사용된 폴리올이 프로필렌 글리콜인 것을 특징으로 하는 조성물.
- 제 3항에 있어서, 붕산염/폴리올 복합체에 사용된 폴리올이 프로필렌 글리콜 및 소르비톨인 것을 특징으로 하는 조성물.
- 제 1항에 있어서, 아연 이온을 0.04 내지 0.4 mM의 농도로 포함하는 것을 특징으로 하는 조성물.
- 제 6항에 있어서, 조성물중 완충 음이온의 농도가 5 mM 미만인 것을 특징으로 하는 조성물.
- 제 1항에 있어서, 조성물중에 아연을 제외한 다가 금속 양이온의 농도가 5 mM 미만인 것을 특징으로 하는 조성물.
- 제 1항에 있어서, 조성물중에 이온화된 염의 농도가 50 mM 미만인 것을 특징으로 하는 조성물.
- 제 1항에 있어서,(i) 조성물중에 아연 이온의 농도가 0.1 내지 0.4 mM이고;(ii) 조성물중에 다가 완충 음이온의 농도가 5 mM 미만이며;(iii) 조성물중에 다가 금속 양이온의 농도가 5 mM 미만이고;(iv) 조성물중에 이온화된 염의 농도가 50 mM 미만인 것을 특징으로 하는 조성물.
- 수성 안과 조성물에 아연 이온을 포함시킴으로써 상기 조성물의 항균 활성을 강화하는 방법으로서, 조성물중에 아연 이온을 0.04 내지 0.9 mM의 농도로 이용하고, 조성물중에 완충 음이온의 농도를 15 mM 미만으로 제한하는 것을 포함하는 개선 (improvement)이 있는 방법.
- 제 11항에 있어서, 개선이 조성물중에 붕산염/폴리올 복합체를 포함하는 것을 추가로 포함하는 것을 특징으로 하는 방법.
- 제 12항에 있어서, 상기 붕산염/폴리올 복합체에 사용된 폴리올이 프로필렌 글리콜인 것을 특징으로 하는 방법.
- 제 11항에 있어서, 조성물중 아연 이온의 농도가 0.04 내지 0.4 mM인 것을 특징으로 하는 방법.
- 제 14항에 있어서, 완충 음이온의 농도가 5 mM 미만인 것을 특징으로 하는 방법.
- 제 11항에 있어서, 개선이 조성물중에 아연을 제외한 다가 양이온의 농도를 5 mM 미만으로 제한하는 것을 추가로 포함하는 것을 특징으로 하는 방법.
- 제 11항에 있어서, 개선이 조성물중에 이온화된 염의 농도를 50 mM 미만으로 제한하는 것을 추가로 포함하는 것을 특징으로 하는 방법.
- 제 11항에 있어서, 아연 이온이 0.1 내지 0.4 mM의 농도로 사용되는 경우 조 성물중에 다가 완충 음이온의 농도가 5 mM 미만의 농도로 제한되고, 조성물중에 아연을 제외한 다가 금속 양이온의 농도가 5 mM 미만의 농도로 제한되며, 조성물중에 이온화된 염의 농도가 50 mM 미만의 농도로 제한되는 것을 특징으로 하는 방법.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82652906P | 2006-09-21 | 2006-09-21 | |
US60/826,529 | 2006-09-21 | ||
US82741106P | 2006-09-28 | 2006-09-28 | |
US60/827,411 | 2006-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090058567A true KR20090058567A (ko) | 2009-06-09 |
KR101021933B1 KR101021933B1 (ko) | 2011-03-16 |
Family
ID=39156274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097007721A KR101021933B1 (ko) | 2006-09-21 | 2007-09-20 | 자기 보존 수성 약제학적 조성물 |
Country Status (22)
Country | Link |
---|---|
US (3) | US8268299B2 (ko) |
EP (1) | EP2068822B2 (ko) |
JP (2) | JP4785970B2 (ko) |
KR (1) | KR101021933B1 (ko) |
AR (1) | AR062929A1 (ko) |
AT (1) | ATE531358T1 (ko) |
AU (1) | AU2007299727B2 (ko) |
BR (1) | BRPI0717067A2 (ko) |
CA (1) | CA2606370C (ko) |
CL (1) | CL2007002705A1 (ko) |
CY (1) | CY1112138T1 (ko) |
DK (1) | DK2068822T4 (ko) |
ES (1) | ES2374444T5 (ko) |
HK (1) | HK1126667A1 (ko) |
MX (1) | MX2009002221A (ko) |
PL (1) | PL2068822T5 (ko) |
PT (1) | PT2068822E (ko) |
RU (1) | RU2436568C2 (ko) |
SI (1) | SI2068822T2 (ko) |
TW (1) | TWI394564B (ko) |
UY (1) | UY30605A1 (ko) |
WO (1) | WO2008036847A2 (ko) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767217B2 (en) | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
TWI394564B (zh) | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
EP2066300B2 (en) | 2006-09-28 | 2019-01-23 | Novartis Ag | Self-preserved aqueous pharmaceutical compositions |
AR066901A1 (es) * | 2007-05-18 | 2009-09-23 | Alcon Mfg Ltd | Composiciones fodfolipidicas para elcuidado de lentes de contacto y conservacion de composiciones farmaceuticas |
WO2009117242A2 (en) † | 2008-03-17 | 2009-09-24 | Alcon Research, Ltd. | Aqueous pharmaceutical compositions containing borate-polyol complexes |
JP2009256281A (ja) * | 2008-04-21 | 2009-11-05 | Teika Seiyaku Kk | イソプロピルウノプロストン含有点眼剤組成物 |
TW201010727A (en) * | 2008-09-03 | 2010-03-16 | Alcon Res Ltd | Pharmaceutical composition having relatively low ionic strength |
EP2367528A1 (en) * | 2008-12-22 | 2011-09-28 | Alcon Research, Ltd. | Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye |
EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
TWI489997B (zh) | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸-多元醇錯合物之水性藥學組成物 |
EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
EP2512230A4 (en) * | 2009-12-15 | 2013-05-22 | Foresight Biotherapeutics Inc | NON-REFRACTORY OPHTHALMIC POVIDONE IOD COMPOSITIONS |
TW201127423A (en) * | 2009-12-17 | 2011-08-16 | Alcon Res Ltd | Ophthalmic solutions with improved disinfection profiles |
SI3287123T1 (sl) | 2011-03-04 | 2020-07-31 | Gruenenthal Gmbh | Vodna farmacevtska formulacija tapentadola za peroralno uporabo |
SI2680833T1 (sl) * | 2011-03-04 | 2016-06-30 | Gruenenthal Gmbh | Parenteralno dajanje tapentadola |
JP6150510B2 (ja) * | 2011-12-12 | 2017-06-21 | ロート製薬株式会社 | 眼科用水性組成物 |
EP2630952A1 (en) | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
TW201417814A (zh) * | 2012-09-28 | 2014-05-16 | Otsuka Pharma Co Ltd | 包括瑞巴派特之醫藥組成物 |
EP2956144B1 (en) * | 2013-02-15 | 2017-11-22 | Senju Pharmaceutical Co., Ltd. | Difluprednate emulsion composition containing zinc |
CA2903718A1 (en) | 2013-03-13 | 2014-10-02 | Cour Pharmaceuticals Development Co., Inc. | Immune-modifying particles for the treatment of inflammation |
EP3037094A1 (en) | 2014-12-23 | 2016-06-29 | Poifa Warszawa SA | Ophthalmic pharmaceutical composition |
MX2017012312A (es) | 2015-03-27 | 2018-01-18 | Gruenenthal Gmbh | Formulacion estable para administracion parenteral de tapentadol. |
US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
US10632202B2 (en) | 2016-03-04 | 2020-04-28 | Johnson & Johnson Consumer Inc. | Preservative containing compositions |
BR112019005439A2 (pt) | 2016-09-23 | 2019-06-18 | Gruenenthal Gmbh | formulação estável para administração parenteral de tapentadol |
WO2019123266A1 (en) | 2017-12-20 | 2019-06-27 | Novartis Ag | Ophthalmic composition having a prostaglandin and a beta-blocker |
EP3861985B1 (en) | 2020-02-06 | 2023-06-14 | Ocular Therapeutix, Inc. | Compositions and methods for treating ocular diseases |
US20220031739A1 (en) * | 2020-07-31 | 2022-02-03 | Eye Therapies Llc | Anti-viral compositions and methods of use thereof |
WO2023054669A1 (ja) | 2021-09-30 | 2023-04-06 | ロート製薬株式会社 | 眼科組成物 |
WO2024003078A1 (en) * | 2022-06-27 | 2024-01-04 | Warszawskie Zaklady Farmaceutyczne Polfa Sa | Preservative-free ophthalmic composition comprising a prostaglandin analogue |
EP4309644A1 (en) * | 2022-07-22 | 2024-01-24 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Preservative-free ophthalmic composition comprising an antiglaucoma agent |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2084870B (en) | 1980-10-10 | 1985-05-09 | Muhlemann R Hans | Oral compositions containing pyrimidine amine compounds and zinc salts |
US5607698A (en) | 1988-08-04 | 1997-03-04 | Ciba-Geigy Corporation | Method of preserving ophthalmic solution and compositions therefor |
IL92351A (en) | 1988-11-29 | 1994-02-27 | Allergan Inc Irvine | Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt |
US5130298A (en) | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
US5221664A (en) | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
EP0564510A1 (en) | 1990-12-27 | 1993-10-13 | Allergan, Inc | Method and composition for disinfecting contact lenses |
US5460834A (en) | 1991-12-13 | 1995-10-24 | Alcon Laboratories, Inc. | Combinations of polymers for use in physiological tear compositions |
EP0639070B2 (en) * | 1992-05-06 | 2010-09-08 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
US5505953A (en) | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5320843A (en) | 1992-12-10 | 1994-06-14 | Polymer Technology Corporation | Method for improving antibacterial properties of ophthalmic solutions |
NZ247516A (en) * | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
TW274516B (ko) | 1993-11-12 | 1996-04-21 | Ciba Geigy Ag | |
WO1996003158A1 (en) | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
US6024954A (en) | 1994-12-12 | 2000-02-15 | Allergan | Compositions and methods for disinfecting contact lenses and preserving contact lens care products |
AU4878996A (en) | 1995-03-20 | 1996-10-08 | Unilever Plc | Liquid cleansing formulations |
US5683993A (en) | 1995-06-22 | 1997-11-04 | Ciba Vision Corporation | Compositions and methods for stabilizing polymers |
HU225329B1 (en) | 1996-09-12 | 2006-09-28 | Richter Gedeon Vegyeszet | Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity |
US6121315A (en) | 1996-09-20 | 2000-09-19 | Warner-Lambert Company | Oral compositions containing a zinc compound |
US5820822A (en) * | 1996-10-25 | 1998-10-13 | Kross; Robert D. | Antimicrobial composition and method of use |
ES2262603T3 (es) | 1996-12-13 | 2006-12-01 | Alcon Laboratories, Inc. | Composiciones oftalmicas que comprenden aminoalcoholes. |
US5858346A (en) | 1997-05-09 | 1999-01-12 | Allergan | Compositions and methods for enhancing contact lens wearability |
CN100408100C (zh) | 1997-07-29 | 2008-08-06 | 阿尔康实验室公司 | 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物 |
US6034043A (en) | 1999-04-20 | 2000-03-07 | Lever Brothers Company, Division Of Conopco, Inc. | Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness |
US6482799B1 (en) | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
US6166012A (en) | 1999-07-30 | 2000-12-26 | Allergan Sales, Inc. | Antibiotic compositions and method for using same |
CA2430127C (en) | 2000-11-29 | 2010-04-20 | Novartis Ag | Aqueous disinfecting system comprising a microbicide and 1,3-bis(tris[hydroxymethyl]methylamino)propane |
AR035509A1 (es) * | 2000-12-21 | 2004-06-02 | Alcon Inc | Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento |
JP4863589B2 (ja) | 2001-09-28 | 2012-01-25 | ロート製薬株式会社 | 水性組成物 |
US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
JP2004339104A (ja) * | 2003-05-14 | 2004-12-02 | Rohto Pharmaceut Co Ltd | 溶液の安定化方法 |
JP4644682B2 (ja) | 2003-12-09 | 2011-03-02 | アルコン、インコーポレイテッド | 水性組成物の抗微生物活性を強化するためのビスアミンの使用 |
US7968122B2 (en) * | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
CA2545947A1 (en) | 2003-12-11 | 2005-07-07 | Alcon, Inc. | Ophthalmic compositions containing a polysaccharide/borate gelling system |
US20050214382A1 (en) * | 2004-03-29 | 2005-09-29 | Erning Xia | Zinc preservative composition and method of use |
GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
US20070212420A1 (en) * | 2006-03-10 | 2007-09-13 | Bausch & Lomb Incorporated | Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives |
US20070297990A1 (en) | 2006-06-27 | 2007-12-27 | Shah Mandar V | Self-preserving composition |
TWI394564B (zh) | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
-
2007
- 2007-09-17 TW TW096134677A patent/TWI394564B/zh active
- 2007-09-20 PT PT07842914T patent/PT2068822E/pt unknown
- 2007-09-20 AR ARP070104170A patent/AR062929A1/es unknown
- 2007-09-20 RU RU2009114849/15A patent/RU2436568C2/ru active
- 2007-09-20 WO PCT/US2007/079082 patent/WO2008036847A2/en active Application Filing
- 2007-09-20 ES ES07842914T patent/ES2374444T5/es active Active
- 2007-09-20 US US11/858,781 patent/US8268299B2/en active Active
- 2007-09-20 SI SI200730811T patent/SI2068822T2/sl unknown
- 2007-09-20 AU AU2007299727A patent/AU2007299727B2/en not_active Ceased
- 2007-09-20 MX MX2009002221A patent/MX2009002221A/es active IP Right Grant
- 2007-09-20 AT AT07842914T patent/ATE531358T1/de active
- 2007-09-20 EP EP07842914.9A patent/EP2068822B2/en active Active
- 2007-09-20 BR BRPI0717067-0A2A patent/BRPI0717067A2/pt not_active Application Discontinuation
- 2007-09-20 CL CL200702705A patent/CL2007002705A1/es unknown
- 2007-09-20 JP JP2009529404A patent/JP4785970B2/ja active Active
- 2007-09-20 DK DK07842914.9T patent/DK2068822T4/da active
- 2007-09-20 CA CA2606370A patent/CA2606370C/en not_active Expired - Fee Related
- 2007-09-20 KR KR1020097007721A patent/KR101021933B1/ko active IP Right Grant
- 2007-09-20 PL PL07842914.9T patent/PL2068822T5/pl unknown
- 2007-09-21 UY UY30605A patent/UY30605A1/es not_active Application Discontinuation
-
2009
- 2009-06-19 HK HK09105567.3A patent/HK1126667A1/xx not_active IP Right Cessation
-
2011
- 2011-04-14 US US13/086,950 patent/US8323630B2/en active Active
- 2011-07-12 JP JP2011154267A patent/JP5411897B2/ja active Active
- 2011-12-02 CY CY20111101200T patent/CY1112138T1/el unknown
-
2012
- 2012-10-30 US US13/664,049 patent/US20130053440A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101021933B1 (ko) | 자기 보존 수성 약제학적 조성물 | |
US8388941B2 (en) | Self preserved aqueous pharmaceutical compositions | |
KR101738502B1 (ko) | 보레이트-폴리올 복합체를 함유하는 수성 약학 조성물 | |
AU2009225931B9 (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
CN101516332B (zh) | 自身防腐的水性药物组合物 | |
US20100021561A1 (en) | Self-preserved aqueous pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140221 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150130 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160218 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170302 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190227 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20200227 Year of fee payment: 10 |